Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.
Type:
Application
Filed:
November 20, 2008
Publication date:
December 31, 2009
Applicant:
DECODE GENETICS EHF
Inventors:
Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov, Adalie Motta, Gary Schiltz, Georgeta Hategan, Timothy Hagen
Abstract: A locus on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers. Diagnostic applications for identifying susceptibilty to cancer are described.
Type:
Application
Filed:
May 18, 2006
Publication date:
December 24, 2009
Applicant:
deCODE genetics ehf.
Inventors:
Laufey Amundadottir, Julius Gudmundsson, Patrick Sulem
Abstract: Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed.
Type:
Application
Filed:
August 3, 2009
Publication date:
November 26, 2009
Applicant:
DECODE GENETICS EHF
Inventors:
Jasbir Singh, Mark E. Gurney, Georgeta Hategan, Peng Yu, David Zembower, Nian Zhou
Abstract: Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes.
Abstract: Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed.
Type:
Grant
Filed:
June 27, 2005
Date of Patent:
October 6, 2009
Assignee:
deCODE genetics ehf
Inventors:
Jasbir Singh, Mark E. Gurney, Georgeta Hategan, Peng Yu, David Zembower, Nian Zhou
Abstract: The present invention relates to a chemical genus of biaryl substituted nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Application
Filed:
May 27, 2009
Publication date:
September 17, 2009
Applicant:
DECODE GENETICS EHF
Inventors:
Vincent Sandanayaka, Jasbir Singh, Mahnaz Keyvan, Michael David Krohn, Mark E. Gurney
Abstract: Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes.
Abstract: The present invention relates to a chemical genus of biaryl substituted nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Grant
Filed:
August 3, 2006
Date of Patent:
August 18, 2009
Assignee:
deCODE genetics ehf
Inventors:
Vincent Sandanayaka, Jasbir Singh, Mahnaz Keyvan, Michael David Krohn, Mark E. Gurney
Abstract: The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Application
Filed:
June 11, 2008
Publication date:
June 25, 2009
Applicant:
deCODE genetics, ehf
Inventors:
Vincent SANDANAYAKA, Jasbir Singh, Mark Gurney, Bjorn Mamat, Peng Yu, Louis Bedell, Lei Zhao, Rama K. Mishra
Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.
Type:
Application
Filed:
November 20, 2008
Publication date:
May 28, 2009
Applicant:
DECODE GENETICS EHF
Inventors:
Jasbir Singh, Mark E. Gurney, Alex Burgin, Alexander Kiselyov, Munagala Rao, Timothy Hagen
Abstract: Compounds of the formula: are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.
Type:
Application
Filed:
November 20, 2008
Publication date:
May 21, 2009
Applicant:
DECODE GENETICS EHF
Inventors:
Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov
Abstract: The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: in which A and B are carbocycles or heterocycles.
Type:
Application
Filed:
November 20, 2008
Publication date:
May 21, 2009
Applicant:
DECODE GENETICS EHF
Inventors:
Jasbir Singh, Mark E. Gurney, Alex Burgin, Alexander Kiselyov, Munagala Rao
Abstract: The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: in which A and B are carbocycles or heterocycles.
Type:
Application
Filed:
November 20, 2008
Publication date:
May 21, 2009
Applicant:
deCODE genetics ehf
Inventors:
Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov, Munagala Rao
Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the gents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia.
Type:
Grant
Filed:
March 26, 2002
Date of Patent:
February 24, 2009
Assignee:
deCODE genetics ehf.
Inventors:
Hreinn Stefansson, Valgerdur Steinthorsdottir, Jeffrey R. Gulcher, Mark Gurney, Thorkell Andresson
Abstract: The invention relates to materials and methods for therapy to inhibit the production of leukotrienes, and therapeutic and prophylactic applications thereof.
Abstract: The invention relates to methods for inducing a pro-asthma/pro-inflammatory like state in a resident tissue cell, comprising contacting the cell with one or more cytokines, e.g., IL-?, TNF? or both. Methods are also disclosed for identifying genes that regulate responses to anti-inflammatory drugs, to methods for drug screening, and to methods for identifying genes that correlate with various pro-asthma/pro-inflammatory disease phenotypes.
Type:
Grant
Filed:
July 16, 2007
Date of Patent:
October 14, 2008
Assignees:
deCODE genetics ehf., The Children's Hospital of Philadelphia
Abstract: This invention provides an automated system for the processing of data packets, composed of personal identifiers and personal data, such that the personally identifiable data sent by one party may be considered anonymous once received by a second party. The invention uses secret sharing techniques to facilitate distributed key management of the mapping functions and strong authentication to allow the system to be operated remotely.
Abstract: Methods are disclosed for predicting the efficacy of a drug for treating an inflammatory disease in a human patient, including: obtaining a sample of cells from the patient; obtaining a gene expression profile of the sample in the absence and presence of in vitro modulation of the cells with specific cytokines and/or mediators; and comparing the gene expression profile of the sample with a reference gene expression profile, wherein similarities between the sample expression profile and the reference expression profile predicts the efficacy of the drug for treating the inflammatory disease in the patient.